Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis

Du, HY; Li, XD; Su, N; Li, L; Hao, XT; Gao, HH; Kwong, JSW; Vandvik, PO; Yang, XL; Nemeth, I; Mordi, IR; Li, QR; Zhang, LH; Rao, L; Lang, CC; Li, JS; Tian, HM; Li, SY

Li, SY (reprint author), Univ Dundee, Sch Med, Dundee DD1 9SY, Scotland.; Li, SY (reprint author), Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu 610041, Sichuan, Peoples R China.; Li, SY (reprint author), Univ Dundee, Ninewells Hosp, Div

HEART, 2019; 105 (15): 1149

Abstract

Background To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE). Metho......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索